{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:28:57Z","timestamp":1772821737525,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","award":["RGP.2\/361\/45"],"award-info":[{"award-number":["RGP.2\/361\/45"]}],"id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-38719-w","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T23:47:19Z","timestamp":1770767239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemical synthesis of novel aminopyrimidin-4-yl-1H-pyrazole derivatives as spleen tyrosine kinase (SYK) inhibitors"],"prefix":"10.1038","volume":"16","author":[{"given":"K. V.","family":"Rajasheker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S.","family":"Pallavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallavi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Stupin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Silina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavitharaj","family":"Varadaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Y.","family":"Alfaifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali A.","family":"Shati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serag Eldin I.","family":"Elbehairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandan","family":"Shivamallu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Manvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. C.","family":"Arun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva Prasad","family":"Kollur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"5","key":"38719_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett, A., Wetzler, M. & L\u00f6wenberg, B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 29 (5), 487\u2013494. https:\/\/doi.org\/10.1200\/JCO.2010.30.1820 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"38719_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ccr.2009.08.018","volume":"16","author":"CK Hahn","year":"2009","unstructured":"Hahn, C. K. et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 16 (4), 281\u2013294. https:\/\/doi.org\/10.1016\/j.ccr.2009.08.018 (2009).","journal-title":"Cancer Cell."},{"issue":"4","key":"38719_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ccell.2017.03.001","volume":"31","author":"S Mohr","year":"2017","unstructured":"Mohr, S. et al. Hoxa9 and Meis1 cooperatively induce addiction to Syk signaling by suppressing miR-146a in acute myeloid leukemia. Cancer Cell. 31 (4), 549\u2013562e511. https:\/\/doi.org\/10.1016\/j.ccell.2017.03.001 (2017).","journal-title":"Cancer Cell."},{"issue":"19","key":"38719_CR4","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.3390\/ijms21197009","volume":"21","author":"G Marchetti","year":"2020","unstructured":"Marchetti, G. et al. Syk inhibitors: new computational insights into their intraerythrocytic action in plasmodium falciparum malaria. Int. J. Mol. Sci. 21 (19), 7009. https:\/\/doi.org\/10.3390\/ijms21197009 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"38719_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pharmthera.2013.02.001","volume":"138","author":"SL Tan","year":"2013","unstructured":"Tan, S. L., Liao, C., Lucas, M. C., Stevenson, C. & DeMartino, J. A. Targeting the SYK\u2013BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Pharmacol. Ther. 138 (2), 294\u2013309. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.02.001 (2013).","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"38719_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","volume":"35","author":"RL Geahlen","year":"2014","unstructured":"Geahlen, R. L. Getting syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol. Sci. 35 (8), 414\u2013422. https:\/\/doi.org\/10.1016\/j.tips.2014.05.007 (2014).","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"38719_CR7","doi-asserted-by":"publisher","first-page":"e87610","DOI":"10.1371\/journal.pone.0087610","volume":"9","author":"J Blancato","year":"2014","unstructured":"Blancato, J. et al. SYK allelic loss and the role of Syk-Regulated genes in breast cancer survival. PLOS ONE. 9 (2), e87610. https:\/\/doi.org\/10.1371\/journal.pone.0087610 (2014).","journal-title":"PLOS ONE"},{"issue":"6","key":"38719_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/leu.2008.77","volume":"22","author":"AL Feldman","year":"2008","unstructured":"Feldman, A. L. et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia 22 (6), 1139\u20131143. https:\/\/doi.org\/10.1038\/leu.2008.77 (2008).","journal-title":"Leukemia"},{"issue":"13","key":"38719_CR9","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1158\/0008-5472.CAN-08-4252","volume":"69","author":"M Buchner","year":"2009","unstructured":"Buchner, M. et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 69 (13), 5424\u20135432. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4252 (2009).","journal-title":"Cancer Res."},{"issue":"1","key":"38719_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.bbamcr.2014.10.022","volume":"1853","author":"MO Krisenko","year":"2015","unstructured":"Krisenko, M. O. & Geahlen, R. L. Calling in SYK: syk\u2019s dual role as a tumor promoter and tumor suppressor in cancer. Biochim. Et Biophys. Acta (BBA) - Mol. Cell. Res. 1853 (1), 254\u2013263. https:\/\/doi.org\/10.1016\/j.bbamcr.2014.10.022 (2015).","journal-title":"Biochim. Et Biophys. Acta (BBA) - Mol. Cell. Res."},{"issue":"24","key":"38719_CR11","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1182\/blood-2011-02-333773","volume":"118","author":"S Cheng","year":"2011","unstructured":"Cheng, S. et al. SYK Inhibition and response prediction in diffuse large B-cell lymphoma. Blood 118 (24), 6342\u20136352. https:\/\/doi.org\/10.1182\/blood-2011-02-333773 (2011).","journal-title":"Blood"},{"issue":"13","key":"38719_CR12","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1182\/blood-2006-05-026203","volume":"108","author":"L Leseux","year":"2006","unstructured":"Leseux, L. et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 108 (13), 4156\u20134162. https:\/\/doi.org\/10.1182\/blood-2006-05-026203 (2006).","journal-title":"Blood"},{"issue":"3","key":"38719_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2141.2005.05883.x","volume":"132","author":"A Rinaldi","year":"2006","unstructured":"Rinaldi, A. et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Haematol. 132 (3), 303\u2013316. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05883.x (2006).","journal-title":"Br. J. Haematol."},{"issue":"1","key":"38719_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/0008-5472.CAN-14-0629","volume":"75","author":"VPS Ghotra","year":"2015","unstructured":"Ghotra, V. P. S. et al. SYK is a candidate kinase target for the treatment of advanced prostate cancer. Cancer Res. 75 (1), 230\u2013240. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0629 (2015).","journal-title":"Cancer Res."},{"issue":"6","key":"38719_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nsmb.2040","volume":"18","author":"P Prinos","year":"2011","unstructured":"Prinos, P. et al. Alternative splicing of SYK regulates mitosis and cell survival. Nat. Struct. Mol. Biol. 18 (6), 673\u2013679. https:\/\/doi.org\/10.1038\/nsmb.2040 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"12","key":"38719_CR16","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1002\/art.38851","volume":"66","author":"ME Weinblatt","year":"2014","unstructured":"Weinblatt, M. E. et al. Effects of Fostamatinib, an oral spleen tyrosine kinase Inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group study. Arthritis Rheumatol. 66 (12), 3255\u20133264. https:\/\/doi.org\/10.1002\/art.38851 (2014).","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"38719_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","volume":"10","author":"A M\u00f3csai","year":"2010","unstructured":"M\u00f3csai, A., Ruland, J. & Tybulewicz, V. L. J. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10 (6), 387\u2013402. https:\/\/doi.org\/10.1038\/nri2765 (2010).","journal-title":"Nat. Rev. Immunol."},{"issue":"15","key":"38719_CR18","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","volume":"125","author":"J Sharman","year":"2015","unstructured":"Sharman, J. et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood 125 (15), 2336\u20132343. https:\/\/doi.org\/10.1182\/blood-2014-08-595934 (2015).","journal-title":"Blood"},{"issue":"236","key":"38719_CR19","doi-asserted-by":"publisher","first-page":"236ra262","DOI":"10.1007\/978-981-99-3810-0_26","volume":"6","author":"T Perova","year":"2014","unstructured":"Perova, T. et al. Therapeutic potential of spleen tyrosine kinase Inhibition for treating High-Risk precursor B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6 (236), 236ra262\u2013236ra262. https:\/\/doi.org\/10.1007\/978-981-99-3810-0_26 (2014).","journal-title":"Sci. Transl. Med."},{"issue":"13","key":"38719_CR20","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg, J. W. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115 (13), 2578\u20132585. https:\/\/doi.org\/10.1182\/blood-2009-08-236471 (2010).","journal-title":"Blood"},{"issue":"10","key":"38719_CR21","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.bmcl.2014.03.075","volume":"24","author":"G Thoma","year":"2014","unstructured":"Thoma, G. et al. Syk inhibitors with high potency in presence of blood. Bioorg. Med. Chem. Lett. 24 (10), 2278\u20132282. https:\/\/doi.org\/10.1016\/j.bmcl.2014.03.075 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"38719_CR22","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.bmcl.2009.02.049","volume":"19","author":"HZ Xie","year":"2009","unstructured":"Xie, H. Z. et al. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Bioorg. Med. Chem. Lett. 19 (7), 1944\u20131949. https:\/\/doi.org\/10.1016\/j.bmcl.2009.02.049 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"38719_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1021\/acsmedchemlett.3c00553","volume":"15","author":"H Jia","year":"2024","unstructured":"Jia, H. et al. Discovery of Sovleplenib, a selective inhibitor of Syk in clinical development for autoimmune diseases and cancers. ACS Med. Chem. Lett. 15 (5), 595\u2013601. https:\/\/doi.org\/10.1021\/acsmedchemlett.3c00553 (2024).","journal-title":"ACS Med. Chem. Lett."},{"key":"38719_CR24","doi-asserted-by":"publisher","unstructured":"Barker, M. D. et al.  Discovery of potent and selective spleen tyrosine kinase inhibitors for the topical treatment of inflammatory skin disease. Bioorg. Med. Chem. Lett. 28 (21), 3458\u20133462. https:\/\/doi.org\/10.1016\/j.bmcl.2018.09.022 (2018).","DOI":"10.1016\/j.bmcl.2018.09.022"},{"issue":"23","key":"38719_CR25","doi-asserted-by":"publisher","first-page":"10414","DOI":"10.1021\/jm301367c","volume":"55","author":"MC Lucas","year":"2012","unstructured":"Lucas, M. C. et al. Rational design of highly selective spleen tyrosine kinase inhibitors. J. Med. Chem. 55 (23), 10414\u201310423. https:\/\/doi.org\/10.1021\/jm301367c (2012).","journal-title":"J. Med. Chem."},{"key":"38719_CR26","doi-asserted-by":"publisher","unstructured":"Kumar, V. et al. 3D-QSAR-Based pharmacophore Modeling, virtual Screening, and molecular dynamics simulations for the identification of spleen tyrosine kinase inhibitors. Front. Cell. Infect. Microbiol. 12, 256.  https:\/\/doi.org\/10.3389\/fcimb.2022.909111 (2022).","DOI":"10.3389\/fcimb.2022.909111"},{"issue":"40","key":"38719_CR27","doi-asserted-by":"publisher","first-page":"11754","DOI":"10.1002\/anie.201506085","volume":"54","author":"DE Smith","year":"2015","unstructured":"Smith, D. E. et al. Exploiting atropisomerism to increase the target selectivity of kinase inhibitors. Angew. Chem. Int. Ed. 54 (40), 11754\u201311759. https:\/\/doi.org\/10.1002\/anie.201506085 (2015).","journal-title":"Angew. Chem. Int. Ed."},{"issue":"9","key":"38719_CR28","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1021\/jm500228a","volume":"57","author":"KS Currie","year":"2014","unstructured":"Currie, K. S. et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J. Med. Chem. 57 (9), 3856\u20133873. https:\/\/doi.org\/10.1021\/jm500228a (2014).","journal-title":"J. Med. Chem."},{"key":"38719_CR29","doi-asserted-by":"publisher","unstructured":"Peter Blomgren, J. et al.  Discovery of Lanraplenib (GS-9876): a once-daily spleen tyrosine kinase inhibitor for autoimmune diseases. ACS Med. Chem. Lett. 11,  506\u2013513.  https:\/\/doi.org\/10.1021\/acsmedchemlett.9b00621 (2020).","DOI":"10.1021\/acsmedchemlett.9b00621"},{"key":"38719_CR30","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40262-022-01135-0","volume":"61","author":"R Matsukane","year":"2022","unstructured":"Matsukane, R., Suetsugu, K., Hirota, T. & Ieiri, I. Clinical pharmacokinetics and pharmacodynamics of fostamatinib and its active moiety R406. Clin. Pharmacokinet. 61, 955\u2013972. https:\/\/doi.org\/10.1007\/s40262-022-01135-0 (2022).","journal-title":"Clin. Pharmacokinet."},{"issue":"16","key":"38719_CR31","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated Docking with selective receptor flexibility. J. Comput. Chem. 30 (16), 2785\u20132791. https:\/\/doi.org\/10.1002\/jcc.21256 (2009).","journal-title":"J. Comput. Chem."},{"key":"38719_CR32","unstructured":"The AutoDock 4.2 User Guide. \/ Manual (Scripps Research Institute) includes details of preparing PDBQT files, adding hydrogens, choosing charges, grid box setup, docking protocols. https:\/\/github.com\/ccsb-scripps\/AutoDock-GPU (2025)."},{"key":"38719_CR33","first-page":"831","volume":"12","author":"SM Rizvi","year":"2013","unstructured":"Rizvi, S. M., Shakil, S. & Haneef, M. A simple click by click protocol to perform docking: autoDock 4.2 made easy for non-bioinformaticians. Excli J. 12, 831\u2013857 (2013). https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4669947\/","journal-title":"Excli J."},{"issue":"16","key":"38719_CR34","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel, D. et al. GROMACS: Fast, flexible, and free. J. Comput. Chem. 26 (16), 1701\u20131718. https:\/\/doi.org\/10.1002\/jcc.20291 (2005).","journal-title":"J. Comput. Chem."},{"issue":"8","key":"38719_CR35","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/prot.22711","volume":"78","author":"K Lindorff-Larsen","year":"2010","unstructured":"Lindorff-Larsen, K. et al. Improved side-chain torsion potentials for the amber ff99SB protein force field. Proteins Struct. Funct. Bioinform. 78 (8), 1950\u20131958. https:\/\/doi.org\/10.1002\/prot.22711 (2010).","journal-title":"Proteins Struct. Funct. Bioinform."},{"issue":"43","key":"38719_CR36","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.1021\/jp003020w","volume":"105","author":"P Mark","year":"2001","unstructured":"Mark, P. & Nilsson, L. Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 K. J. Phys. Chem. A. 105 (43), 9954\u20139960. https:\/\/doi.org\/10.1021\/jp003020w (2001).","journal-title":"J. Phys. Chem. A"},{"key":"38719_CR37","doi-asserted-by":"publisher","unstructured":"Vald\u00e9s-Tresanco, M. S., Vald\u00e9s-Tresanco, M. E., Valiente, P. A. & Moreno, E.  gmx_MMPBSA: a new tool to perform End-State free energy calculations with GROMACS. J. Chem. Theory Comput. 17 (10), 6281\u20136291. https:\/\/doi.org\/10.1021\/acs.jctc.1c00645 (2021).","DOI":"10.1021\/acs.jctc.1c00645"},{"issue":"9","key":"38719_CR38","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR Miller","year":"2012","unstructured":"Miller, B. R. et al. MMPBSA.py: an efficient program for End-State free energy calculations. J. Chem. Theory Comput. 8 (9), 3314\u20133321. https:\/\/doi.org\/10.1021\/ct300418h (2012).","journal-title":"J. Chem. Theory Comput."},{"issue":"3","key":"38719_CR39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/prot.21344","volume":"67","author":"GG Maisuradze","year":"2007","unstructured":"Maisuradze, G. G. & Leitner, D. M. Free energy landscape of a biomolecule in dihedral principal component space: sampling convergence and correspondence between structures and minima. Proteins Struct. Funct. Bioinform. 67 (3), 569\u2013578. https:\/\/doi.org\/10.1002\/prot.21344 (2007).","journal-title":"Proteins Struct. Funct. Bioinform."},{"issue":"4","key":"38719_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/1062936x.2024.2345618","volume":"35","author":"D Danishuddin","year":"2024","unstructured":"Danishuddin, D., Malik, M. Z., Kashif, M., Haque, S. & Kim, J. J. Exploring chemical space, scaffold diversity, and activity landscape of spleen tyrosine kinase active inhibitors. SAR QSAR Environ. Res. 35 (4), 325\u2013342. https:\/\/doi.org\/10.1080\/1062936x.2024.2345618 (2024).","journal-title":"SAR QSAR Environ. Res."},{"issue":"5","key":"38719_CR41","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1021\/ac3023422","volume":"85","author":"AM Lipchik","year":"2013","unstructured":"Lipchik, A. M. & Parker, L. L. Time-Resolved luminescence detection of spleen tyrosine kinase activity through terbium sensitization. Anal. Chem. 85 (5), 2582\u20132588. https:\/\/doi.org\/10.1021\/ac3023422 (2013).","journal-title":"Anal. Chem."},{"key":"38719_CR42","doi-asserted-by":"publisher","unstructured":"Tong, M. et al. Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites. Nat. Commun. 8, 1. https:\/\/doi.org\/10.1038\/s41467-017-02240-6 (2017).","DOI":"10.1038\/s41467-017-02240-6"},{"issue":"9","key":"38719_CR43","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/leu.2008.163","volume":"22","author":"C Yang","year":"2008","unstructured":"Yang, C. et al. Tyrosine kinase Inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 22 (9), 1755\u20131766. https:\/\/doi.org\/10.1038\/leu.2008.163 (2008).","journal-title":"Leukemia"},{"issue":"2","key":"38719_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1089\/154065804323056503","volume":"2","author":"P Singh","year":"2004","unstructured":"Singh, P., Lillywhite, B. J., Harden, B. J. & Broad, P. M. Identification of kinase inhibitors by an ATP depletion method. Assay Drug Dev. Technol. 2 (2), 161\u2013169. https:\/\/doi.org\/10.1089\/154065804323056503 (2004).","journal-title":"Assay Drug Dev. Technol."},{"issue":"6","key":"38719_CR45","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1089\/adt.2009.0222","volume":"7","author":"H Zegzouti","year":"2009","unstructured":"Zegzouti, H., Zdanovskaia, M., Goueli, S. A. & Hsiao, K. ADP-Glo: a bioluminescent and homogeneous ADP monitoring assay for kinases. Assay Drug Dev. Technol. 7 (6), 560\u2013572. https:\/\/doi.org\/10.1089\/adt.2009.0222 (2009).","journal-title":"Assay Drug Dev. Technol."},{"key":"38719_CR46","doi-asserted-by":"publisher","unstructured":"Olivieri, C. et al. ATP-competitive inhibitors modulate the substrate binding cooperativity of a kinase by altering its conformational entropy. Sci. Adv. 8, 30. https:\/\/doi.org\/10.1126\/sciadv.abo0696 (2022).","DOI":"10.1126\/sciadv.abo0696"},{"issue":"47","key":"38719_CR47","doi-asserted-by":"publisher","first-page":"6484","DOI":"10.1021\/acs.biochem.6b00859","volume":"55","author":"I Rivalta","year":"2016","unstructured":"Rivalta, I. et al. Allosteric communication disrupted by a small molecule binding to the imidazole glycerol phosphate synthase Protein-Protein interface. Biochemistry 55 (47), 6484\u20136494. https:\/\/doi.org\/10.1021\/acs.biochem.6b00859 (2016).","journal-title":"Biochemistry"},{"issue":"6","key":"38719_CR48","doi-asserted-by":"publisher","first-page":"e0157509","DOI":"10.1371\/journal.pone.0157509","volume":"11","author":"CE Grimshaw","year":"2016","unstructured":"Grimshaw, C. E. et al. SYR-472, Zafatek), novel Once-Weekly treatment for type 2 Diabetes, inhibits dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent mechanism. PLOS ONE. 11 (6), e0157509. https:\/\/doi.org\/10.1371\/journal.pone.0157509 (2016).","journal-title":"PLOS ONE"},{"issue":"5","key":"38719_CR49","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/cpt.3390","volume":"116","author":"HX Ngo","year":"2024","unstructured":"Ngo, H. X., Wen, Y. W., Pisupati, S., Huang, W. & Mandlekar, S. A. Comparative clinical Pharmacology analysis of FDA-Approved targeted covalent inhibitors vs. Reversible inhibitors in oncology. Clin. Pharmacol. Ther. 116 (5), 1198\u20131206. https:\/\/doi.org\/10.1002\/cpt.3390 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"38719_CR50","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.3390\/ijms22052608","volume":"22","author":"R Ahn","year":"2021","unstructured":"Ahn, R. & Ursini-Siegel, J. Clinical potential of kinase inhibitors in combination with immune checkpoint inhibitors for the treatment of solid tumors. Int. J. Mol. Sci. 22 (5), 2608. https:\/\/doi.org\/10.3390\/ijms22052608 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"49","key":"38719_CR51","doi-asserted-by":"publisher","first-page":"17019","DOI":"10.1021\/jacs.8b08008","volume":"140","author":"PM Cromm","year":"2018","unstructured":"Cromm, P. M., Crews, C. M., Hines, J. & Samarasinghe, K. T. G. Addressing Kinase-Independent functions of Fak via PROTAC-Mediated degradation. J. Am. Chem. Soc. 140 (49), 17019\u201317026. https:\/\/doi.org\/10.1021\/jacs.8b08008 (2018).","journal-title":"J. Am. Chem. Soc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38719-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38719-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38719-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:34:54Z","timestamp":1772800494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38719-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38719"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38719-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8323"}}